Autopsy report · NCT03044353

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Change in benefit/risk profile”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 year before it started.
Ran for about 1 year 6 months before it stopped.
7 participants enrolled.
Results were posted on the registry 9 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: GlaxoSmithKline
Sponsor type: Industry
Conditions: Amyloidosis
Interventions: GSK2315698 (CPHPC); GSK2398852 (anti-SAP mAb)
Participants: 7
Sites: 3
Countries: United Kingdom, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.